Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study

Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mult Scler
Egile Nagusiak: Hagens, Marloes HJ, Killestein, Joep, Yaqub, Maqsood M, van Dongen, Guus AMS, Lammertsma, Adriaan A, Barkhof, Frederik, van Berckel, Bart NM
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2017
Gaiak:
Short Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891689/
https://ncbi.nlm.nih.gov/pubmed/28443358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517704507
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak